download autodesk softimage 2015 go to buy matlab uk cheapest microsoft office 2007 standard price of adobe photoshop lightroom buy contribute cs4 license here here where to buy pinnacle video transfer here buy windows xp full version to click buy adobe acrobat standard 9 upgrade where can i buy cyberlink powerdirector 9 deluxe cost of office 2010 pro plus
go to here http://edwards.sdsu.edu/scaffold_builder... reason 5 student discount to click best price photoshop cs5 extended buy paperport professional 12 best buy punch home landscape design suite cheap adobe photoshop elements 7 cheap indesign cs5 here microsoft frontpage purchase buy quicken 2008 home business here here

GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

Sat, Oct 15, 2011

Oral Cancer News

Source: http://7thspace.com
Author: Chien-Yu Lin et al.

Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance an important issue.
Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and oral cancer cell lines. In this study, we determined clinical significance of GP96 in ORC by evaluation of GP96 expression and its association with disease prognosis in patients receiving radiotherapy

Methods:
Total of 79 ORC patients (77 males, median age: 48 years old) receiving radical surgery and postoperative radiotherapy between Oct 1999 and Dec 2004 were enrolled.

Patients in pathological stages II, III and IV were 16.5%, 16.5% and 67%, respectively. For each patient, a pair of carcinoma tissue and grossly adjacent normal mucosa was obtained.

GP96-expression was examined by western blot analysis, and the association with clinicopathological status was determined.

Results:
Three-year locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) rates were 69%, 79%, 63% and 57%, respectively. We found that 55 patients (70%) displayed GP96-overexpression in the tumor tissue, which correlated with a higher pN stage (p=0.020) and tumor depth (>10 mm) (p=0.045).

Nodal extracapsular spreading (ECS) and GP96-overexpression predicted adverse LRC (p=0.049 and p=0.008). When stratified by nodal ECS, the adverse impact of GP96 remained significant in three-year LRC (p=0.004).

In multivariate analysis, GP96-overexpression was also an independent predictor of LRC, DSS and OS (p=0.018, p=0.011 and p=0.012).

Conclusion:
GP96 may play roles in radioresistance which attributes to tumor invasiveness in oral cancer patients receiving radiotherapy. GP96 may serve as a novel prognostic marker of radiotherapy.

However, further independent studies are required to validate our findings in a larger series.

Authors: Chien-Yu Lin, Ting-Yang Lin, Hung-Ming Wang, Shiang-Fu Huang, Kang-Hsing Fan, Chun-Ta Liao, I-How Chen, Li-Yu Lee, Yan-Liang Li, Yin-Ju Chen, Ann-Joy Cheng, Joseph Chang

Source: Radiation Oncology 2011, 6:136

Print Friendly
Be Sociable, Share!
, , , , ,

Leave a Reply

You must be logged in to post a comment.